Drugs / miridesap
miridesap
also known as
GSK2315698 · CPHPC · (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid · RO-638695
Small molecule targets APCS
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02953808 | Nov → Dec 2016 | amyloidosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01777243 | May 2013 → Dec 2015 | amyloidosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01406314 | Oct 2011 → Nov 2012 | amyloidosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01323985 | Jan → Jun 2011 | amyloidosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02425241 | Oct 2013 → Feb 2016 | HIV infectious disease | University College, London | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03044353 | Jul 2017 → Jan 2019 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03417830 Background | Apr → Jul 2018 | amyloidosis | GlaxoSmithKline | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | miridesap | “The drug (R)-1-[6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC, miridesap), developed for treatment of systemic amyloidosis and...” PMID 29772028 ↗ May 20181“The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP” PMID 29298867 ↗ Jan 2018 |
| Known as | (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid | “The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP” PMID 29298867 ↗ Jan 2018 |
| Known as | CPHPC | “The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP” PMID 29298867 ↗ Jan 2018 |
| Known as | GSK2315698 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01406314 ↗ |
| Known as | RO-638695 | ChEMBL registry synonym — accepted as the source's own label CHEMBL25263 ↗ |
| Modality | Small molecule | “The small-molecule drug, miridesap” PMID 29298867 ↗ Jan 2018 |
| Route | Intravenous | “a single intravenous (IV) infusion over a short time period” NCT01323985 ↗ |
| Target | APCS | “Serum amyloid P-component cross-linking agent” CHEMBL25263 ↗ |